Advancing Regulatory Pathways for Aurkine Chemotherapeutics to First-in Human Trials

Project Leader: Jesús M. Bañales

Partners: Fernando P. Cossío, Angela Lamarca, Aitana Calvo

Funding agency: Fundación "La Caixa" - Convocatoria CaixaImpulse Innovation 2026

Period: 01/12/2026 - 30/11/2028

Amount: 150.000 EUR

Developing a consensus statement of the determination of HER2 in biliary tract tumors

Coordinators: Angela Lamarca, Chiara Braconi, Rocio IR Macias

Funding agency: Jazz Pharmaceuticals  

Period: june 2026-june 2027

Amount: 25,000 €

SAFIR IMPACT BTC: precision medicine in biliary tract cancer

International Coordinator: Julien Edeline.  

Team members: David Malka, John Bridgewater, Ivan Borbath, Timon Vandamme, Marjolein Homs, Angela Lamarca, Lorenza Rimassa, Anna Saborowski, Arndt Vogel, Mia Johansson, Grainne O'Kane. Patients' advocates Helen Morement (AMMF), Lilian Lecorgne (Espoir voies biliaires), Elisabeth Baucels (ATUVIBI), Paolo Leonardi (APIC), Lili Anna Kuschnereit (DiCE)

Funding agency: ATTRACT (Accelerate Together Rare Cancer Treatment) consortium; ARC, anticancer fund, fundacion cientifica contra el cancer, Kom op tegen Kanker, KWF and Rising Tide

Reference: SAFIR IMPACT BTC

Period: end 2026-end 2030

Amount: 5,100,000 €

Novel Cancer Therapy: Inducing Double-strand DNA Breaks to Foster Tumour Cell Death, Antigenicity and Immunotherapy Response in New Personalized Models (TITAN)

Participants: Coordinator - Jesus M. Banales; CoPIs - Fernando Cossio, Michela Polidoro, Jean-Charles Nault, Elena Palma

Funding agency: European Union’s Horizon 2020

Reference TRANSCAN-3 Joint Call (JTC) 2024

Peridod: end 2026-end 2028

Amount: 1,197,300 €

Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary tract Cancer (PREDICT-BC)

Participants: Coordinator - Anna Saborowski. CoPIs - Arndt Vogel, Oreste Segatto, Gregory Schwartz, Mariano Ponz, Tian Tian

Funding agency: European Union’s Horizon 2020

Reference TRANSCAN-3 Joint Call (JTC) 2024

Peridod: end 2026-end 2028

Amount: 1,304,000 €